MINIMAL RESIDUAL DISEASE IN THE CLINICAL PRACTICE OF MULTIPLE MYELOMA PATIENTS

被引：0
|
作者：
Cedena, M. T. [1 ]
Puig, N. [2 ]
Paiva, B. [3 ]
Perez, A. [4 ]
De Arriba, F. [5 ]
Cuellar, C. [1 ]
Blanchard, M. J. [6 ]
Martinez-Chamorro, C. [7 ]
Casanova, M. [8 ]
Sirvent, M. [9 ]
Rodriguez-Otero, P. [3 ]
Martinez-Lopez, J. [1 ]
Mateos, M., V [2 ]
San Miguel, J. F. [3 ]
Lahuerta, J. J. [1 ]
机构：
[1] Hosp 12 Octubre, Madrid, Spain
[2] Hosp Univ Salamanca, Salamanca, Spain
[3] Clin Univ Navarra, Pamplona, Spain
[4] Hosp Son Espases, Palma De Mallorca, Illes Balears, Spain
[5] Hosp JM Morales Meseguer, Murcia, Spain
[6] Hosp Ramon & Cajal, Madrid, Spain
[7] Hosp Quirosalud Madrid, Madrid, Spain
[8] Complejo Hosp Costa del Sol, Malaga, Spain
[9] Hosp Donostia, San Sebastian, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO-013
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma.
    Mohan, Meera
    Yarlagadda, Naveen Kumar
    Atwal, Dinesh
    Pandey, Yadav
    Roy, Arya
    Parikh, Richa
    Lopez, James
    Thanendrarajan, Sharmilan
    Schinke, Carolina D.
    Alapat, Daisy
    Van Rhee, Frits
    Kendrick, Samantha
    Zangari, Maurizio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
    Foureau, David M.
    Paul, Barry A.
    Guo, Fei
    Lipford, Edward H.
    Fesenkova, Kateryna
    Tjaden, Elise
    Drummond, Kendra
    Bhutani, Manisha
    Atrash, Shebli
    Ndiaye, Ami
    Varga, Cindy
    Voorhees, Peter M.
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (01): : E41 - E50
  • [43] Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari, Shalin
    Hillengass, Jens
    McCarthy, Philip L.
    Holstein, Sarah A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 39 - 46
  • [44] Multiple myeloma patient perceptions of minimal residual disease testing
    Hydren, Jay
    Martinez, Jorge Arturo Hurtado
    Quiroz, Felipe Flores
    Perez, Patricia Alejandra Flores
    Espinoza, Andrea Isabel Robles
    Vicencio, Andrea Jimena Cuevas
    Flores, Marilu Najera
    Hernandez, Eduardo Franco
    Aldana, Ana Sahagun Sanchez
    Sweeney, Nathan
    Ahlstrom, Jennifer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S74 - S74
  • [45] Minimal residual disease in multiple myeloma: Benefits of flow cytometry
    Galtseva, I. V.
    Davydova, Y. O.
    Kapranov, N. M.
    Julhakyan, H. L.
    Mendeleeva, L. P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (01) : 12 - 20
  • [46] Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Mailankody, Sham
    Korde, Neha
    Lesokhin, Alexander M.
    Lendvai, Nikoletta
    Hassoun, Hani
    Stetler-Stevenson, Maryalice
    Landgren, Ola
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) : 286 - U139
  • [47] Minimal residual disease in multiple myeloma: bringing the bench to the bedside
    Sham Mailankody
    Neha Korde
    Alexander M. Lesokhin
    Nikoletta Lendvai
    Hani Hassoun
    Maryalice Stetler-Stevenson
    Ola Landgren
    Nature Reviews Clinical Oncology, 2015, 12 : 286 - 295
  • [48] Progress in the application of minimal residual disease detection in multiple myeloma
    Xiaojia Zuo
    Dingsheng Liu
    Journal of Hematopathology, 2021, 14 : 97 - 107
  • [49] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Nishihori, Taiga
    Song, Jinming
    Shain, Kenneth H.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2016, 11 (02) : 118 - 126
  • [50] Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Taiga Nishihori
    Jinming Song
    Kenneth H. Shain
    Current Hematologic Malignancy Reports, 2016, 11 : 118 - 126
12345